Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01257919 · ClinicalTrials.gov registry record · Phase 1

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

A Phase 1 study, sponsored by LEO Pharma.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target

NCT01257919 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01257919, a Phase 1 study, has completed, sponsored by LEO Pharma.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target

Study Summary

Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.

Interventions

  • DRUG Azelaic Acid Foam
  • DRUG Azelaic Acid Gel

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2011-01
Est. Completion 2011-03
Phase Phase 1

Sponsor

LEO Pharma

65 total trials

What the Registry Record Tells You About NCT01257919

The ClinicalTrials.gov registry entry for NCT01257919 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Azelaic Acid Foam is the first listed.

NCT01257919 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01257919 about?

NCT01257919 is a clinical study titled "Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea". Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.

What is the current status of trial NCT01257919?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-01. Estimated completion is 2011-03.

What interventions are being tested in trial NCT01257919?

The interventions under investigation include: Azelaic Acid Foam (DRUG), Azelaic Acid Gel (DRUG).

Who is sponsoring clinical trial NCT01257919?

This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.